A qualidade de vida infantil no panorama em mudança da reumatologia pediátrica

Abstract

et al. A cluster-randomized trial of benchmarking and multimodal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams. Pediatrics. 2007;119:876-90 Prior to their introduction, the therapeutic armamentarium was not only limited in its extent and toxicity but also by its efficacy. On the other hand, the available tools assessing outcome were narrowly focused, literally applied from the adult literature, untested and mainly failed to assess the true impact of a therapeutic approach, which ultimately remains the only relevant one, QOL.The article by Klatchoian et al. 1 from São Paulo, Brazil, which this editorial is dedicated to, examines the validity of a QOL score in a Brazilian population of children with systemic lupus (SLE) and juvenile arthritis (JA).In the latter population, it has finally been recognized that these diseases can persist into adulthood causing disability, pain, and physical dysfunction. The author is member of Scientific Advisory Board at Abbott Laboratories, Pfizer, Merck, Novartis, Promotional SpeakersBureau -Amgen Inc., Wyeth Pharmaceuticals, Abbott.Suggested citation: Reiff A. Childhood quality of life in the changing landscape of pediatric rheumatology.